Today on Health in 2 Point 00, the survey says digital health is optimistic! Find out more on the other side. On Episode 207, Jess asks me about Aetion getting $110 million bringing its total to $212 million working on real world evidence for pharma companies, and Indonesian telehealth company Halodoc gets $80 million. MSK startup Vori Health gets $45 million—can they compete with Hinge? Next, Heartbeat Health gets $20 million for cardiovascular health. Finally, Andreesen throws $10.5 million in a Series A to Memora Health which is a patient messaging system. Don’t forget to join us on Clubhouse tonight for more! —Matthew Holt
With 3 consecutive days of $100M in funding, here is the most confusing (or rather the most confused we have been) Episode 147 of Health in 2 Point 00. Jess asks me about Verily partnering with Swiss Re to get into the stop-loss insurance game, Prescryptive Health raising a $26M Series A for their maybe GoodRx-like or PBM platform, Sonde Health acquiring NeuroLex for its vocal biomarkers platform, Aetion reopening their Series B and raising another $19M to the $36M they have already raised, and Otsuka after investing millions of dollars in Proteus, deciding to buy the rest of it with $15M, but we don’t know why any of these deals happened –Matthew HoltContinue reading…
Today on THCB Spotlights, Matthew interviews Carolyn Magill, CEO of Aetion. Aetion is a real world evidence analytics company working to accelerate time to regulatory grade insights. In fact, Aetion recently did a study with Horizon Blue Cross Blue Shield of New Jersey where they analyzed the type 2 diabetes population, identified a subset of patients who should be on a different class of drugs—which are more expensive—that would improve health outcomes and bring down the total cost of care, saving about $5 million for Horizon. Find out where the data and intelligence for this platform came from, and how this female CEO works to empower women both internally and externally.
By JESSICA DAMASSA, WTF HEALTH
Big news from Aetion CEO, Carolyn Magil, as she talks about the addition of former FDA Commissioner, Scott Gottlieb, to her Board. WHOA. What a HUGE endorsement of support for what Aetion is building…which is what, exactly? Carolyn explains how the company is using real world data (any data outside of clinical trial data) to figure out how different people will react to the same drug. That means they’re using data from health insurance claims, EMRs, wearables, pharma registries, etc. to ultimately save the time, money, and headache of finding out which medicines will work best for which patients. What’s more? A priority for Aetion is helping bring to light how populations usually under-represented in clinical trials (women, seniors, kids) will react to certain treatments. Backed by $77M in funding, and now the former FDA head, tune in to find out what’s next for Aetion.
Filmed at the HIMSS Health 2.0 Conference in Santa Clara, CA in September 2019.
Today on Health in 2 Point 00, there appears to be money falling from the sky… There’s been a lot of funding going on this week. In this episode, Jess asks me about Livongo acquiring myStrength, which provides digital behavioral health solutions; Medicare Advantage startup Clover Health’s $500 million raise; real-world data analytics platform Aetion’s $27 million raise; men’s wellness company Hims’ $100 million raise; and urine analysis company Healthy.io’s $18 million raise. Be sure to stay tuned for next week’s big preview episode of HIMSS.—Matthew Holt.
It’s not every day that an analytics firm focusing on improving the efficacy and value of drugs has a big raise in the health tech world–especially one I don’t know much about. This morning Aetion raised $36m to add onto $11m they raised last year. Their new round is led by famed venture firm NEA and includes Amgen Ventures. I spoke to CEO and part-time extreme skier Carolyn Magill to find out what Aetion does and why big pharma and major payers need their help in the brave new world of value-based care.